全文获取类型
收费全文 | 677篇 |
免费 | 76篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 50篇 |
妇产科学 | 6篇 |
基础医学 | 96篇 |
口腔科学 | 28篇 |
临床医学 | 73篇 |
内科学 | 186篇 |
皮肤病学 | 20篇 |
神经病学 | 34篇 |
特种医学 | 85篇 |
外科学 | 67篇 |
综合类 | 17篇 |
预防医学 | 17篇 |
药学 | 43篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 2篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 3篇 |
2019年 | 9篇 |
2018年 | 16篇 |
2017年 | 7篇 |
2016年 | 12篇 |
2015年 | 17篇 |
2014年 | 18篇 |
2013年 | 32篇 |
2012年 | 27篇 |
2011年 | 32篇 |
2010年 | 48篇 |
2009年 | 31篇 |
2008年 | 24篇 |
2007年 | 29篇 |
2006年 | 21篇 |
2005年 | 24篇 |
2004年 | 12篇 |
2003年 | 22篇 |
2002年 | 13篇 |
2001年 | 19篇 |
2000年 | 10篇 |
1999年 | 14篇 |
1998年 | 31篇 |
1997年 | 36篇 |
1996年 | 34篇 |
1995年 | 29篇 |
1994年 | 20篇 |
1993年 | 19篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 14篇 |
1988年 | 19篇 |
1987年 | 16篇 |
1986年 | 12篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 11篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1974年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有758条查询结果,搜索用时 15 毫秒
61.
Kashyap SR Belfort R Cersosimo E Lee S Cusi K 《Journal of the CardioMetabolic Syndrome》2008,3(3):141-146
Elevated plasma triglyceride/free fatty acid (FFA) levels and insulin resistance may promote atherosclerosis through endothelial activation (ie, increased expression of intercellular adhesion molecule 1 [ICAM-1]/vascular adhesion molecule 1 [VCAM-1], and endothelin-1 [ET-1]) in patients with the metabolic syndrome, but this has never been directly tested. The authors measured endothelial activation and insulin sensitivity (euglycemic insulin clamp with [3-(3)H]-glucose) after a 4-day low-dose lipid infusion that elevated plasma FFA to levels observed in the metabolic syndrome in 20 lean, non-diabetic insulin-resistant subjects with a strong family history of type 2 diabetes mellitus (FH(+)) and 10 insulin-sensitive volunteers without a family history of type 2 diabetes mellitus (FH(-)). Low-dose lipid infusion reduced insulin sensitivity by approximately 25% in insulin-sensitive FH(-)controls but did not worsen preexisting insulin resistance in FH(+). Low-dose lipid infusion elevated plasma ICAM and VCAM levels similarly in both groups (approximately 12%-18%; P<.01 vs baseline), while plasma ET-1 levels increased more in FH(+)vs FH(-)(46% vs 10%; P=.005). Increased plasma FFA levels closely correlated with elevated ICAM (r=0.60; P<.01), VCAM, and ET-1 levels (r=0.39 and r=0.42, respectively; P<.05). Low-dose lipid infusion induces endothelial activation in both lean insulin-resistant (FH(+)) and insulin-sensitive (FH(-)) healthy patients, regardless of changes in insulin sensitivity. These results prove that even a modest lipid oversupply may be sufficient to trigger a deleterious endothelial response. 相似文献
62.
63.
64.
Cusi M Tsung J Nouh F Wong L Mansberg R Van der Wall H 《Clinical nuclear medicine》2007,32(9):737-738
A 14-year-old girl presented with a painful right foot. She was an elite water-polo player and could recall no history of specific trauma to the foot. On close and persistent questioning, she admitted to having taken up playing the drums recently, with practice sessions of up to 4 h/d. She used the foot drum with her right foot and had noticed that this was becoming increasingly painful and prevented her playing the instrument for the last 2 days. Plain films of the foot were originally reported as normal, but revised to abnormal after the scintigraphic study. Bone scintigraphy confirmed a stress fracture of the right 3rd metatarsal bone. Stress fractures of the 3rd metatarsal bone are rare with only 2 previous reports in the literature. 相似文献
65.
A Choppin I Irwin L Lach MG McDonald AE Rettie L Shao C Becker MP Palme X Paliard S Bowersox DM Dennis P Druzgala 《British journal of pharmacology》2009,158(6):1536-1547
Background and purpose:
Tecarfarin (ATI-5923) is a novel vitamin K epoxide reductase inhibitor that is metabolized by esterase (mainly human carboxylesterase 2) to a single major metabolite, ATI-5900, in rats, dogs and humans. Tecarfarin is not significantly metabolized by CYP450 enzymes. The objective of this study was to test and compare the efficacy of tecarfarin with that of warfarin, when administered either intravenously or once a day orally, to produce stable anticoagulation in beagle dogs.Experimental approach:
Effects on coagulation were assessed by measuring the activity levels of Factor VII and Factor X and thromboplastin-induced coagulation times, reported as prothrombin time (PT).Key results:
Continuous intravenous infusions and oral administration of tecarfarin and warfarin caused a dose-dependent decrease in activity of Factor VII and Factor X, and associated increase in PT. Intravenous fresh frozen canine plasma or subcutaneous vitamin K1 treatment reversed the anticoagulant effects of orally administered tecarfarin. Consistent with the inhibitory effects of amiodarone on CYP2C9, co-administration of amiodarone significantly increased the anticoagulation effect of warfarin and plasma warfarin concentrations. In contrast, amiodarone had no effect on the anticoagulation induced by tecarfarin or tecarfarin plasma concentrations in this model.Conclusions and implications:
Overall, the data presented herein indicate that tecarfarin, via a vitamin K-dependent mechanism, causes changes in key parameters of haemostasis in beagle dogs that are consistent with effective anticoagulation. Compared to warfarin it has a decreased potential to interact metabolically with drugs that inhibit CYP450 enzymes and, therefore, may offer an improved safety profile for patients. 相似文献66.
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs 总被引:1,自引:0,他引:1
Correale P Del Vecchio MT La Placa M Montagnani F Di Genova G Savellini GG Terrosi C Mannucci S Giorgi G Francini G Cusi MG 《Journal of immunotherapy (Hagerstown, Md. : 1997)》2008,31(2):132-147
The effects of anticancer chemotherapy on antigen-specific cytotoxic T lymphocytes (CTLs) are mostly unknown. We tested the effects of cytotoxic drugs such as 5-fluorouracil, gemcitabine, and oxaliplatin on the functional activity of antigen-specific CTL cultures derived from the peripheral blood mononuclear cells of human donors. We found that a biweekly drug-exposure of human HLA-A(*)02.01+ CTLs derived from bulk cultures led to completely different effects if occurring early (day second) or late (day thirteenth) after the in vitro stimulations with the cognate peptides. In the first case, there was a significant CTL inhibition, whereas in the second, there was a marked enhancement of the antigen-specific cytolytic activity. Results of immunocytofluorimetric studies and CTL/natural killer inhibition assays suggested that the latter effect could be related to a more selective drug-mediated inhibition of cohabitant T regulatory (reg) cells. These results were translated in an in vivo therapeutic mouse model where humanized HLA-A(*)02.01 transgenic mice inoculated with EL-4/humanized HLA-A(*)02.01 transgenic mice showed a prolonged survival and the greatest rate of cure when receiving a combined treatment with a thymidylate synthase-specific peptide vaccine and a multidrug chemotherapy regimen administered late after immunization. Tumor samples derived from this group of mice showed a reduced expression of the target thymidylate synthase antigen, a marked reduction of T(reg)s, and a noteworthy infiltration of C8+ T cells. These results may have clinical implications for the design of new translational anticancer regimens aimed at combining chemotherapy and immunotherapy. 相似文献
67.
A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge 总被引:1,自引:0,他引:1
Scardino A Alimandi M Correale P Smith SG Bei R Firat H Cusi MG Faure O Graf-Dubois S Cencioni G Marrocco J Chouaib S Lemonnier FA Jackson AM Kosmatopoulos K 《Cancer research》2007,67(14):7028-7036
A cDNA vaccine (pVax1/pet-neu) was designed to encode 12 different Her-2/ErbB-2-derived, HLA-A*0201-restricted dominant and high-affinity heteroclitic cryptic epitopes. Vaccination with pVax1/pet-neu triggered multiple and ErbB-2-specific CTL responses in HLA-A*0201 transgenic HHD mice and in HLA-A*0201 healthy donors in vitro. Human and murine CTL specific for each one of the 12 ErbB-2 peptides recognized in vitro both human and murine tumor cells overexpressing endogenous ErbB-2. Furthermore, vaccination of HHD mice with pVax1/pet-neu significantly delayed the in vivo growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) more actively when compared with vaccination with the empty vector (pVax1) or vehicle alone. These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes. 相似文献
68.
A Ascari‐Raccagni A Dondas MG Righini G Trevisan 《Journal of the European Academy of Dermatology and Venereology》2010,24(8):926-929
Background The repair of an alar nasal defect is a frequent challenge for dermatologic surgeons for reasons of the high rate of non‐melanoma cancers in the area. Objective Our aim was to describe the use of an east–west cheek‐based flap (horizontal advancement flap) to repair a surgical defect on the nose ala. Methods Benefits and limits of this surgical procedure are evaluated. Result The resulting S‐shaped scar was well‐camouflaged among the natural skin lines (melolabial fold and melonasal junction). No architectural distortion of the nose resulted from the procedure. Conclusion In selected patients with small‐to‐medium‐size defects of the nasal ala, the horizontal advancement flap is a simple, reliable and aesthetic reconstruction option. 相似文献
69.
70.